Navigation Links
OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib
Date:3/18/2008

fied by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the potential benefits of bevasiranib, our ability to establish OPKO's leadership position, our ability to aggressively engage in R&D activities and advance clinical testing of bevasiranib and our ability to develop a preclinical pipeline of novel agents for ophthalmic diseases, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those factors described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that enrollment of patients for the Phase III clinical trial for bevasiranib, may not be successful, that the Phase III clinical trial itself may not be completed on a timely basis or at all, that any of our compounds under development, including bevasiranib, may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date
'/>"/>
SOURCE OPKO Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 ... purchase of an Irys™System by BGI ... platform to enable comprehensive exploration of human structural variation ... organisms of interest, including those where no reference exists. ... develop new methods for multiplexing on the Irys System, ...
(Date:7/31/2014)... IL (PRWEB) July 31, 2014 ... of automation across the U.S., increasing unemployment, depressing ... class. It is a Catch 22—we need ... but this means fewer jobs,” says economist and ... just-released Pollina Corporate Top 10 Pro-Business States for ...
(Date:7/31/2014)... 2014 Sales Horizons, a leader in ... sales training course – Mastering the Complex Sale ... , Drawn from proven sales training programs used by ... Complex Sale online sales training course is available to ... face-to-face contact with customers, like technical support, engineers, clinical ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
Breaking Biology Technology:BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... July 23 Best Practices, LLC is a,research, ... in the,field of best practice benchmarking focused on ... Best Practices, LLC is,conducting business function specific Webinars ... Web-Conferences Scheduled in July 2008, Best Practices, ...
... - Chromos Molecular,Systems Inc. ("Chromos" or the "Company") ... authorities in the Provinces,of British Columbia, Alberta, Manitoba, ... against the Company effective July 22, 2008. As ... outstanding against the,Company., The Company continues to ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ("Duska") announced ... of a proposed Phase 3 clinical study for,its ... Drug Administration,s (the,"FDA") Division of Cardiovascular and Renal ... FDA, including a face-to-face,meeting held on April 16, ...
Cached Biology Technology:Web-Conferences by Best Practices, LLC for July 2008 2Chromos Announces Full Revocation of Cease Trade Orders 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4
(Date:7/31/2014)... shown that marine noise can affect animal movement and ... of Bristol and Exeter and the cole Pratique des ... boat noise stops embryonic development and increases larval mortality ... slug Stylocheilus striatus used in this study) ... later feed on toxic alga but this study, conducted ...
(Date:7/30/2014)... the way for a breakthrough that may prevent ... to poisonous chemicalsparticularly those in pesticides and chemical ... issue of the journal ChemBioChem outlines ... commonly used in pesticides and warfare agents. The ... Engineering Associate Professor of Chemical and Biological Engineering ...
(Date:7/30/2014)... the Red Queen in Lewis Carroll,s Through the ... and National University of Singapore improved a 35-year-old ... over decades to millions of years. , The ... competition, incorporates the "Red Queen Effect," an evolutionary ... 1970s, which suggests that organisms must constantly increase ...
Breaking Biology News(10 mins):Boat noise impacts development and survival of sea hares 2Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... to all living things can make hibernating marmots hungry ... obesity and eating disorders, according to a new study ... appears in the current issue of the Journal ... at http://jeb.biologists.org/cgi/reprint/213/12/2031 . Professor Greg Florant discovered ...
... Michigan State University scientists have developed a pioneering, comprehensive ... and wetlands more integrated and effective. "We call ... professor of fisheries and wildlife. "It,s a new way ... lakes, rivers and wetlands as they interact with ...
... U.S. economic stimulus program (ARRA) Health Information Technology for ... use of health information technology (HIT) and to ready ... leading members of the American Medical Informatics Association (AMIA), ... decades has advocated for informatics as a health care ...
Cached Biology News:Marmots can teach us about obesity 2Innovative MSU research makes lake and stream conservation more effective 2AMIA Members Manage HITECH Stimulus Grant Awards 2
The imaging screen-K (Kodak), tritium, is a 20 x 25 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
... 175 tube gel cell is a stand-alone ... 2-D electrophoresis applications. The upper buffer chamber ... 9-23 cm long for isoelectric focusing (IEF) ... chamber and cooling core, lower buffer chamber, ...
Biology Products: